From small to big molecules: How do we prevent and delay the progression of age- related neurodegeneration?

Current Pharmaceutical Design

Volumn 18, Issue 1, 2012, Pages 15-26

  Ho, Yuen Shan ^a   Poon, David Chun Hei ^a   Chan, Tin Fung ^a   Chang, Raymond Chuen Chung ^a,b,c  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Age related macular degeneration; Alzheimer's disease; Flavonoids; Glycoconjugates; Parkinson's disease; Resveratrol; Stilbenes

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANTIOXIDANT; APIGENIN; ASCORBIC ACID; CATECHIN; CYANIDIN 3 GLUCOSIDE; DAIDZEIN; EPIGALLOCATECHIN GALLATE; ERIODICTYOL; FLAVANOL DERIVATIVE; FLAVANONE; FLAVONOID; GALLOCATECHIN; GENISTEIN; KAEMPFEROL; LUTEOLIN; NARINGENIN; NEUROPROTECTIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NUTRACEUTICAL; OLIGOSACCHARIDE; PHENOL DERIVATIVE; POLYSACCHARIDE; PROANTHOCYANIDIN; QUERCETIN; RESVERATROL; STILBENE; TAU PROTEIN; UNINDEXED DRUG;

AGE RELATED NEURODEGENERATION; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; CLINICAL FEATURE; DISEASE COURSE; DRUSEN; GERIATRIC DISORDER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; INTRACELLULAR SIGNALING; MOOD DISORDER; NERVE CELL; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK FACTOR; SENILE PLAQUE; SUBSTANTIA NIGRA;

EID: 84855827849     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212798919039     Document Type: Review

References (165)

1. Maalouf M, Rho JM, Mattson MP. The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies. Brain Res Rev 2009; 59: 293-315.
2. Scarmeas N, Stern Y, Tang MX, Mayeux R, Luchsinger JA. Mediterranean diet and risk for Alzheimer's disease. Ann Neuro 2006; 59: 912-21.
3. Gasior M, Rogawski MA, Hartman AL. Neuroprotective and disease-modifying effects of the ketogenic diet. Behav Pharmaco 2006; 17: 431-9.
4. Scarmeas N, Luchsinger JA, Schupf N, et al. Physical activity, diet, and risk of Alzheimer disease. JAMA 2009; 302: 627-37.
5. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010; 362: 329-44.
6. Schapira AH, Tolosa E. Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat Rev Neurol 2010; 6: 309-17.
7. Luthert PJ. Pathogenesis of age-related macular degeneration. Diagn Histopathol 2011; 17: 10-16.
8. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004; 122: 598-14.
9. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004; 82: 844-51.
10. Curcio CA, Medeiros NE, Millican CL. Photoreceptor loss in agerelated macular degeneration. Invest Ophthalmol Vis Sci 1996; 37: 1236-49.
11. Maguire P, Vine AK. Geographic atrophy of the retinal pigment epithelium. Am J Ophthalmol 1986; 102: 621-5.
12. Algvere PV, Marshall J, Seregard S. Age-related maculopathy and the impact of blue light hazard. Acta Ophthalmol Scand 2006; 84: 4-15.
13. Mozaffarieh M, Sacu S, Wedrich A. The role of the carotenoids, lutein and zeaxanthin, in protecting against age-related macular degeneration: A review based on controversial evidence. Nutr J 2003; 2: 20.
14. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 1995; 39: 367-74.
15. Ding JD, Lin J, Mace BE, Herrmann R, Sullivan P, Bowes Rickman C. Targeting age-related macular degeneration with Alzheimer's disease based immunotherapies: anti-amyloid-beta antibody attenuates pathologies in an age-related macular degeneration mouse model. Vision Res 2008; 48: 339-45.
16. Luibl V, Isas JM, Kayed R, Glabe CG, Langen R, Chen J. Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. J Clin Invest 2006; 116: 378-85.
17. Agostinho P, Cunha RA, Oliveira C. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. Curr Pharm Des 2010; 16: 2766-78.
18. Gao HM, Kotzbauer PT, Uryu K, Leight S, Trojanowski JQ, Lee VM. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci 2008; 28: 7687-98.
19. Su BN, Cuendet M, Hawthorne ME, et al. Constituents of the bark and twigs of Artocarpus dadah with cyclooxygenase inhibitory activity. J Natural Prod 2002; 65: 163-9.
20. Engelhart MJ, Geerlings MI, Ruitenberg A, et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 2002; 287: 3223-9.
21. Grodstein F, Chen J, Willett WC. High-dose antioxidant supplements and cognitive function in community-dwelling elderly women. Am J Clin Nutr 2003; 77: 975-84.
22. Masaki KH, Losonczy KG, Izmirlian G, et al. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 2000; 54: 1265-72.
23. Khan MM, Ahmad A, Ishrat T, et al. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease. Brain Res 2010; 1328: 139-51.
24. Richard T, Pawlus AD, Iglesias ML, et al. Neuroprotective properties of resveratrol and derivatives. Ann N Y Acad Sci 2011; 1215: 103-8.
25. Sun AY, Wang Q, Simonyi A, Sun GY. Botanical phenolics and brain health. Neuromolecular Med 2008; 10: 259-74.
26. Cho E, Seddon JM, Rosner B, Willett WC, Hankinson SE. Prospective study of intake of fruits, vegetables, vitamins, and carotenoids and risk of age-related maculopathy. Arch Ophthalmol 2004; 122: 883-92.
27. Fletcher AE, Bentham GC, Agnew M, et al. Sunlight exposure, antioxidants, and age-related macular degeneration. Arch Ophthalmol 2008; 126: 1396-403.
28. in t' Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001; 345: 1515-21.
29. McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging 2007; 28: 639-47.
30. Szekely CA, Zandi PP. Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence. CNS Neurol Disord Drug Targets 2010; 9: 132-9.
31. Heneka MT, Kummer MP, Weggen S, et al. Molecular mechanisms and therapeutic application of NSAIDs and derived compounds in Alzheimer's disease. Curr Pharm Des 2011; 8: 115-31.
32. Di Bona D, Scapagnini G, Candore G, et al. Immune-inflammatory responses and oxidative stress in Alzheimer's disease: therapeutic implications. Curr Pharm Des 2010; 16: 684-91.
33. Lue LF, Kuo YM, Beach T, Walker DG. Microglia activation and anti-inflammatory regulation in Alzheimer's disease. Mol Neurobiol 2010; 41: 115-28.
34. Qian L, Flood PM, Hong JS. Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy. J Neural Transm 2010; 117: 971-9.
35. Karagianni N, Adamis AP. The case for complement and inflammation in AMD: open questions. Adv Exp Med Biol 2010; 703: 1-7.
36. Flicker L. Modifiable lifestyle risk factors for Alzheimer's disease. J Alzheimers Dis 2010; 20: 803-11.
37. Beeri MS, Schmeidler J, Silverman JM, Gandy S, Wysocki M, Hannigan CM, et al. Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology 2008; 71: 750-7.
38. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001; 322: 1447-51.
39. Zoccolella S, dell'Aquila C, Specchio LM, Logroscino G, Lamberti P. Elevated homocysteine levels in Parkinson's Disease: is there anything besides L-dopa treatment? Curr Med Chem 2010; 17: 213-21.
40. Costello S, Cockburn M, Bronstein J, Zhang X, Ritz B. Parkinson's disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. Am J Epidemiol 2009; 169: 919-26.
41. Guo L, Duggan J, Cordeiro MF. Alzheimer's disease and retinal neurodegeneration. Curr Alzheimer Res 2010; 7: 3-14.
42. Watson GS, Leverenz JB. Profile of cognitive impairment in Parkinson's disease. Brain Pathol 2010; 20: 640-5.
43. Chiu K CT, Wu A, Leung IYP, So KF, Chang RCC. Neurodegeneration of retina in mouse models of Alzheimer's disease. What can we learn from the retina? Age 2011; In press. (DOI 10.1007/s11357-011-9260-2
44. Blanks JC, Torigoe Y, Hinton DR, Blanks RH. Retinal pathology in Alzheimer's disease. I. Ganglion cell loss in foveal/parafoveal retina. Neurobiol Aging 1996; 17: 377-84.
45. Isas JM, Luibl V, Johnson LV, et al. Soluble and mature amyloid fibrils in drusen deposits. Invest Ophthalmol Vis Sci 2010; 51: 1304-10.
46. Dentchev T, Milam AH, Lee VM, Trojanowski JQ, Dunaief JL. Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. Mol Vis 2003; 9: 184-90.
47. Ding JD, Lin J, Mace BE, Herrmann R, Sullivan P, Bowes Rickman C. Targeting age-related macular degeneration with Alzheimer's disease based immunotherapies: anti-amyloid-beta antibody attenuates pathologies in an age-related macular degeneration mouse model. Vis Res 2008; 48: 339-45.
48. D'Archivio M, Filesi C, Di Benedetto R, Gargiulo R, Giovannini C, Masella R. Polyphenols, dietary sources and bioavailability. Ann Ist Super Sanita 2007; 43: 348-61.
49. Manach C, Scalbert A, Morand C, Remesy C, Jimenez L. Polyphenols: food sources and bioavailability. Am J Clin Nutr 2004; 79: 727-47.
50. Vauzour D, Vafeiadou K, Rodriguez-Mateos A, Rendeiro C, Spencer JP. The neuroprotective potential of flavonoids: a multiplicity of effects. Genes Nutr 2008; 3: 115-26.
51. Rice-Evans CA, Miller NJ, Paganga G. Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic Biol Med 1996; 20: 933-56.
52. Mullie P, Clarys P, Deriemaeker P, Hebbelinck M. Estimation of daily human intake of food flavonoids. Plant Foods Hum Nutr 2007; 62: 93-8.
53. Salah N, Miller NJ, Paganga G, Tijburg L, Bolwell GP, Rice-Evans C. Polyphenolic flavanols as scavengers of aqueous phase radicals and as chain-breaking antioxidants. Arch Biochem Biophys 1995; 322: 339-46.
54. Queen BL, Tollefsbol TO. Polyphenols and aging. Curr Aging Sci 2010; 3: 34-42.
55. Weinreb O, Amit T, Mandel S, Youdim MB. Neuroprotective molecular mechanisms of (-)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties. Genes Nutr 2009; 4: 283-96.
56. Ansari MA, Abdul HM, Joshi G, Opii WO, Butterfield DA. Protective effect of quercetin in primary neurons against Abeta(1-42): relevance to Alzheimer's disease. J Nutr Biochem 2009; 20: 269-75.
57. Ishige K, Schubert D, Sagara Y. Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms. Free Radic Biol Med 2001; 30: 433-46.
58. Jomova K, Vondrakova D, Lawson M, Valko M. Metals, oxidative stress and neurodegenerative disorders. Mol Cellular Biochem 2010; 345: 91-104.
59. Levites Y, Weinreb O, Maor G, Youdim MB, Mandel S. Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. Journal Neurochem 2001; 78: 1073-82.
60. Spencer JP. Flavonoids: modulators of brain function? Br J Nutr 2008; 99 (E Suppl 1): ES60-77.
61. Kelsey NA, Wilkins HM, Linseman DA. Nutraceutical antioxidants as novel neuroprotective agents. Molecules 2010; 15: 7792-814.
62. Vafeiadou K, Vauzour D, Lee HY, Rodriguez-Mateos A, Williams RJ, Spencer JP. The citrus flavanone naringenin inhibits inflammatory signalling in glial cells and protects against neuroinflammatory injury. Arch Biochem Biophys 2009; 484: 100-9.
63. Sorond FA, Lipsitz LA, Hollenberg NK, Fisher ND. Cerebral blood flow response to flavanol-rich cocoa in healthy elderly humans. Neuropsychiatr Dis Treat 2008; 4: 433-40.
64. Baker J, Wolinski K. Isomerization of stilbene using enforced geometry optimization. J Comput Chem 2011; 32: 43-53.
65. Shen T, Wang XN, Lou HX. Natural stilbenes: an overview. Nat Prod Rep 2009; 26: 916-35.
66. Szekeres T, Fritzer-Szekeres M, Saiko P, Jager W. Resveratrol and resveratrol analogues--structure-activity relationship. Pharmacol Res 2010; 27: 1042-8.
67. Marambaud P, Zhao H, Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem 2005; 280: 37377-82.
68. Wang Q, Xu J, Rottinghaus GE, et al. Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res 2002; 958: 439-47.
69. Lee MK, Kang SJ, Poncz M, Song KJ, Park KS. Resveratrol protects SH-SY5Y neuroblastoma cells from apoptosis induced by dopamine. Exp Mol Med 2007; 39: 376-84.
70. Dasgupta B, Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci 2007; 104: 7217-22.
71. Ramadori G, Gautron L, Fujikawa T, Vianna CR, Elmquist JK, Coppari R. Central administration of resveratrol improves dietinduced diabetes. Endocrinology 2009; 150: 5326-33.
72. Minakawa M, Kawano A, Miura Y, Yagasaki K. Hypoglycemic effect of resveratrol in type 2 diabetic model db/db mice and its actions in cultured L6 myotubes and RIN-5F pancreatic beta-cells. J Clin Biochem Nutr 2011; 48: 237-44.
73. Yang R, Zhang H, Zhu L. Inhibitory effect of resveratrol on the expression of the VEGF gene and proliferation in renal cancer cells. Mol Med Report 2011; In press. (DOI: 10.3892/mmr.2011.511)
74. Vanamala J, Reddivari L, Radhakrishnan S, Tarver C. Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer 2010; 10: 238.
75. Cui X, Jin Y, Hofseth AB, et al. Resveratrol suppresses colitis and colon cancer associated with colitis. Cancer Prev Res 2010; 3: 549-59.
76. Yang Y, Wang X, Zhang L, An H, Zao Z. Inhibitory effects of resveratrol on platelet activation induced by thromboxane a(2) receptor agonist in human platelets. Am J Chin Med 2011; 39: 145-59.
77. Robich MP, Osipov RM, Chu LM, et al. Resveratrol modifies risk factors for coronary artery disease in swine with metabolic syndrome and myocardial ischemia. Eur J Pharmacol 2011; 664: 45-53.
78. la Porte C, Voduc N, Zhang G, et al. Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet 2010; 49: 449-54.
79. Almeida L, Vaz-da-Silva M, Falcao A, et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res 2009; 53 (Suppl 1): S7-15.
80. Urpi-Sarda M, Jauregui O, Lamuela-Raventos RM, et al. Uptake of diet resveratrol into the human low-density lipoprotein. Identification and quantification of resveratrol metabolites by liquid chromatography coupled with tandem mass spectrometry. Anal Chem 2005; 77: 3149-55.
81. Chachay VS, Kirkpatrick CM, Hickman IJ, Ferguson M, Prins JB, Martin JH. Resveratrol-pills to replace a healthy diet? Br J Clin Pharmacol 2011; 72: 27-38.
82. Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, Brown K. Clinical trials of resveratrol. Ann N Y Acad Sci 2011; 1215: 161-9.
83. Walle T, Hsieh F, DeLegge MH, Oatis JE, Jr., Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004; 32: 1377-82.
84. Cheng JC, Fang JG, Chen WF, Zhou B, Yang L, Liu ZL. Structureactivity relationship studies of resveratrol and its analogues by the reaction kinetics of low density lipoprotein peroxidation. Bioorg Chem 2006; 34: 142-57.
85. Shang YJ, Qian YP, Liu XD, et al. Radical-scavenging activity and mechanism of resveratrol-oriented analogues: influence of the solvent, radical, and substitution. J Org Chem 2009; 74: 5025-31.
86. Murias M, Jager W, Handler N, et al. Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structureactivity relationship. Biochem Pharmacol 2005; 69: 903-12.
87. Saiko P, Szakmary A, Jaeger W, Szekeres T. Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat Res 2008; 658: 68-94.
88. Mokni M, Elkahoui S, Limam F, Amri M, Aouani E. Effect of resveratrol on antioxidant enzyme activities in the brain of healthy rat. Neurochem Res 2007; 32: 981-7.
89. Khanapure SP, Garvey DS, Janero DR, Letts LG. Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers. Curr Top Med Chem 2007; 7: 311-40.
90. Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425: 191-6.
91. Tang BL, Chua CE. SIRT1 and neuronal diseases. Mol Aspects Med 2008; 29: 187-200.
92. Chao J, Li H, Cheng KW, Yu MS, Chang RC, Wang M. Protective effects of pinostilbene, a resveratrol methylated derivative, against 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells. J Biol Chem 2010; 21: 482-9.
93. Lu KT, Chiou RY, Chen LG, et al. Neuroprotective effects of resveratrol on cerebral ischemia-induced neuron loss mediated by free radical scavenging and cerebral blood flow elevation. J Agric Food Chem 2006; 54: 3126-31.
94. Kennedy DO, Wightman EL, Reay JL, et al. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am J Clin Nutr 2010; 91: 1590-7.
95. Chan HC, Chang RCC, Ip KC, et al. Neuroprotective effects of Lycium barbarum Lynn on protecting retinal ganglion cells in an ocular hypertension model of glaucoma. Exp Neurol 2007; 203: 269-273.
96. Chan WK, Cheung CC, Law HK, Lau YL, Chan GC. Ganoderma lucidum polysaccharides can induce human monocytic leukemia cells into dendritic cells with immuno-stimulatory function. J Hematol Oncol 2008; 1: 9.
97. Ho YS, Yu MS, Yik SY, So KF, Yuen WH, Chang RCC. Polysaccharides from wolfberry antagonizes glutamate excitotoxicity in rat cortical neurons. Cell Mol Neurobiol 2009; 29: 1233-44.
98. Laurienzo P. Marine polysaccharides in pharmaceutical applications: an overview. Mar Drugs 2010; 8: 2435-24.
99. Zhou S, Yang Y, Gu X, Ding F. Chitooligosaccharides protect cultured hippocampal neurons against glutamate-induced neurotoxicity. Neurosci Lett 2008; 444: 270-4.
100. Harish Prashanth KV, Dharmesh SM, Jagannatha Rao KS, Tharanathan RN. Free radical-induced chitosan depolymerized products protect calf thymus DNA from oxidative damage. Carbohydr Res 2007; 342: 190-5.
101. Mendis E, Kim MM, Rajapakse N, Kim SK. An in vitro cellular analysis of the radical scavenging efficacy of chitooligosaccharides. Life Sci 2007; 80: 2118-27.
102. Xu W, Huang HC, Lin CJ, Jiang ZF. Chitooligosaccharides protect rat cortical neurons against copper induced damage by attenuating intracellular level of reactive oxygen species. Bioorg Med Chem Lett 2010; 20: 3084-8.
103. Kim MS, Sung MJ, Seo SB, Yoo SJ, Lim WK, Kim HM. Watersoluble chitosan inhibits the production of pro-inflammatory cytokine in human astrocytoma cells activated by amyloid beta peptide and interleukin-1beta. Neurosci Lett 2002; 321: 105-9.
104. Byun HG, Kim YT, Park PJ, Lin X, Kim SK. Chitooligosaccharides as a novel beta-secretase inhibitor. Carbohydr Polymers 2005; 61: 198-202.
105. Je JY, Kim SK. Water-soluble chitosan derivatives as a BACE1 inhibitor. Bioorg Med Chem 2005; 13: 6551-5.
106. Yoon NY, Ngo DN, Kim SK. Acetylcholinesterase inhibitory activity of novel chitooligosaccharide derivatives. Carbohydr Polymers 2009; 78: 869-72.
107. Yu MS, Leung SK, Lai SW, et al. Neuroprotective effects of antiaging oriental medicine Lycium barbarum against beta-amyloid peptide neurotoxicity. Exp Gerontol 2005; 40: 716-27.
108. Zhu J, Zhao LH, Zhao XP, Chen Z. Lycium barbarum polysaccharides regulate phenotypic and functional maturation of murine dendritic cells. Cell Biol Int 2007; 31: 615-9.
109. Lin CL, Wang CC, Chang SC, Inbaraj BS, Chen BH. Antioxidative activity of polysaccharide fractions isolated from Lycium barbarum Linnaeus. Int J Biol Macromol 2009; 45: 146-51.
110. Yu MS, Lai CS, Ho YS, et al. Characterization of the effects of anti-aging medicine Fructus lycii on beta-amyloid peptide neurotoxicity. Int J Mol Med 2007; 20: 261-8.
111. Ho YS, Yu MS, Yang XF, So KF, Yuen WH, Chang RCC. Neuroprotective effects of polysaccharides from wolfberry, the fruits of Lycium barbarum, against homocysteine-induced toxicity in rat cortical neurons. J Alzheimers Dis 2010; 19: 813-27.
112. Guillozet-Bongaarts AL, Garcia-Sierra F, Reynolds MR, et al. Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease. Neurobiol Aging 2005; 26: 1015-22.
113. Hunot S, Vila M, Teismann P, et al. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc Natl Acad Sci 2004; 101: 665-70.
114. Pons M, Cousins SW, Csaky KG, Striker G, Marin-Castano ME. Cigarette smoke-related hydroquinone induces filamentous actin reorganization and heat shock protein 27 phosphorylation through p38 and extracellular signal-regulated kinase 1/2 in retinal pigment epithelium: implications for age-related macular degeneration. Am J Pathol 2010; 177: 1198-213.
115. Yu MS, Ho YS, So KF, Yuen WH, Chang RCC. Cytoprotective effects of Lycium barbarum against reducing stress on endoplasmic reticulum. Int J Mol Med 2006; 17: 1157-61.
116. Kim SY, Lee EJ, Kim HP, Kim YC, Moon A. A novel cerebroside from lycii fructus preserves the hepatic glutathione redox system in primary cultures of rat hepatocytes. Biol Pharm Bull 1999; 22: 873-5.
117. Li XM, Ma YL, Liu XJ. Effect of the Lycium barbarum polysaccharides on age-related oxidative stress in aged mice. J Ethnopharmacol 2006; 111: 504-11.
118. Niu AJ, Wu JM, Yu DH, Wang R. Protective effect of Lycium barbarum polysaccharides on oxidative damage in skeletal muscle of exhaustive exercise rats. Int J Biol Macromol 2008; 42: 447-9.
119. Li SY, Yang D, Yeung CM, et al. Lycium barbarum polysaccharides reduce neuronal damage, blood-retinal barrier disruption and oxidative stress in retinal ischemia/reperfusion injury. PLoS One 2011; 6: e16380.
120. Chan HC, Chang RCC, Koon-Ching Ip A, et al. Neuroprotective effects of Lycium barbarum Lynn on protecting retinal ganglion cells in an ocular hypertension model of glaucoma. Exp Neurol 2007; 203: 269-73.
121. Ho YS, Yu MS, Lai CS, So KF, Yuen WH, Chang RCC. Characterizing the neuroprotective effects of alkaline extract of Lycium barbarum on beta-amyloid peptide neurotoxicity. Brain Res 2007; 1158C: 123-34.
122. Chiu K, Zhou Y, Yeung SC, et al. Up-regulation of crystallins is involved in the neuroprotective effect of Wolfberry on survival of retinal ganglion cells in rat ocular hypertensionmodel. J Cell Biochem 2010; 110: 311-20.
123. Lemke MR, Fuchs G, Gemende I, et al. Depression and Parkinson's disease. J Neurol 2004; 251 (Suppl 6): VI/24-VI/27.
124. Wuwongse S, Chang RCC, Law AC. The putative neurodegenerative links between depression and Alzheimer's disease. Prog Neurobiol 2010; 91: 362-75.
125. Zhang E, Chang RCC, So KF. Elucidating beneficial effects of Wolfberry (Lycium barbarum) in experimental depression. Society for Neuroscience 2009 2010: 540.13/X7.
126. Li YF, Gong ZH, Yang M, Zhao YM, Luo ZP. Inhibition of the oligosaccharides extracted from Morinda officinalis, a Chinese traditional herbal medicine, on the corticosterone induced apoptosis in PC12 cells. Life Sci 2003; 72: 933-42.
127. Li YF, Liu YQ, Yang M, et al. The cytoprotective effect of inulintype hexasaccharide extracted from Morinda officinalis on PC12 cells against the lesion induced by corticosterone. Life Sci 2004; 75: 1531-8.
128. Yang Z, Yi Y, Gao C, Hou D, Hu J, Zhao M. Isolation of inulintype oligosaccharides from Chinese traditional medicine: Morinda officinalis How and their characterization using ESI-MS/MS. J Sep Sci 2010; 33: 120-5.
129. Zhou X, Wang D, Sun P, et al. Effects of soluble tea polysaccharides on hyperglycemia in alloxan-diabetic mice. J Agric Food Chem 2007; 55: 5523-8.
130. Luo Q, Cai Y, Yan J, Sun M, Corke H. Hypoglycemic and hypolipidemic effects and antioxidant activity of fruit extracts from Lycium barbarum. Life Sci 2004; 76: 137-49.
131. Qin X, Yamauchi R, Aizawa K, Inakuma T, Kato K. Structural features of arabinogalactan-proteins from the fruit of Lycium chinense Mill. Carbohydr Res 2001; 333: 79-85.
132. Ferrari CC, Tarelli R. Parkinson's disease and systemic inflammation. Parkinsons Dis 2011; 2011: 436813.
133. Seddon JM, Gensler G, Milton RC, Klein ML, Rifai N. Association between C-reactive protein and age-related macular degeneration. JAMA 2004; 291: 704-10.
134. Chiu CJ, Klein R, Milton RC, Gensler G, Taylor A. Does eating particular diets alter the risk of age-related macular degeneration in users of the Age-Related Eye Disease Study supplements? Br J Ophthalmol 2009; 93: 1241-6.
135. Xie QM, Deng JF, Deng YM, Shao CS, Zhang H, Ke CK. Effects of cryptoporus polysaccharide on rat allergic rhinitis associated with inhibiting eotaxin mRNA expression. J Ethnopharmacol 2006; 107: 424-30.
136. Wismar R, Brix S, Laerke HN, Frokiaer H. Comparative analysis of a large panel of non-starch polysaccharides reveals structures with selective regulatory properties in dendritic cells. Mol Nutr Food Res, 2011; 55: (3) 443-54.
137. Fang X, Yu MM, Yuen WH, Zee SY, Chang RCC. Immune modulatory effects of Prunella vulgaris L. on monocytes/macrophages. Int J Mol Med 2005; 16: 1109-16.
138. Fang X, Chang RCC, Yuen WH, Zee SY. Immune modulatory effects of Prunella vulgaris L. Int J Mol Med 2005; 15: 491-6.
139. Brown L, Kroon PA, Das DK, et al. The biological responses to resveratrol and other polyphenols from alcoholic beverages. Alcohol Clinical Exp Res 2009; 33: 1513-23.
140. Yamamoto N, Moon JH, Tsushida T, Nagao A, Terao J. Inhibitory effect of quercetin metabolites and their related derivatives on copper ion-induced lipid peroxidation in human low-density lipoprotein. Arch Biochem Biophys 1999; 372: 347-54.
141. Spencer JP, Schroeter H, Crossthwaithe AJ, Kuhnle G, Williams RJ, Rice-Evans C. Contrasting influences of glucuronidation and O-methylation of epicatechin on hydrogen peroxide-induced cell death in neurons and fibroblasts. Free Rad Biol Med 2001; 31: 1139-46.
142. Kalt W, Blumberg JB, McDonald JE, Vinqvist-Tymchuk MR, Fillmore SA, Graf BA, et al. Identification of anthocyanins in the liver, eye, and brain of blueberry-fed pigs. J Agric Food Chem 2008; 56: 705-12.
143. Peng HW, Cheng FC, Huang YT, Chen CF, Tsai TH. Determination of naringenin and its glucuronide conjugate in rat plasma and brain tissue by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1998; 714: 369-74.
144. Abd El, Mohsen MM, Kuhnle G, et al. Uptake and metabolism of epicatechin and its access to the brain after oral ingestion. Free Radic Biol Med 2002; 33: 1693-02.
145. Youdim KA, Dobbie MS, Kuhnle G, Proteggente AR, Abbott NJ, Rice-Evans C. Interaction between flavonoids and the blood-brain barrier: in vitro studies. J Neurochem 2003; 85: 180-92.
146. Youdim KA, Qaiser MZ, Begley DJ, Rice-Evans CA, Abbott NJ. Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic Biol Med 2004; 36: 592-604.
147. Yoshino S, Hara A, Sakakibara H, et al. Effect of quercetin and glucuronide metabolites on the monoamine oxidase-A reaction in mouse brain mitochondria. Nutrition 2011; 27: 847-52.
148. Unno K, Ishikawa Y, Takabayashi F, et al. Daily ingestion of green tea catechins from adulthood suppressed brain dysfunction in aged mice. Biofactors 2008; 34: 263-71.
149. Kishido T, Unno K, Yoshida H, et al. Decline in glutathione peroxidase activity is a reason for brain senescence: consumption of green tea catechin prevents the decline in its activity and protein oxidative damage in ageing mouse brain. Biogerontology 2007; 8: 423-30.
150. Unno K, Takabayashi F, Yoshida H, et al. Daily consumption of green tea catechin delays memory regression in aged mice. Biogerontology 2007; 8: 89-95.
151. Unno K, Takabayashi F, Kishido T, Oku N. Suppressive effect of green tea catechins on morphologic and functional regression of the brain in aged mice with accelerated senescence (SAMP10). Exp Gerontol 2004; 39: 1027-34.
152. Scheepens A, Tan K, Paxton JW. Improving the oral bioavailability of beneficial polyphenols through designed synergies. Genes Nutr 2010; 5: 75-87.
153. Athar M, Back JH, Tang X, et al. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 2007; 224: 274-83.
154. Wenzel E, Somoza V. Metabolism and bioavailability of transresveratrol. Mol Nutr Food Res 2005; 49: 472-81.
155. Jung SH, Kang KD, Ji D, et al. The flavonoid baicalin counteracts ischemic and oxidative insults to retinal cells and lipid peroxidation to brain membranes. Neurochem Int 2008; 53: 325-37.
156. Huang H, Zhang Y, Yang R, Tang X. Determination of baicalin in rat cerebrospinal fluid and blood using microdialysis coupled with ultra-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 874: 77-83.
157. Li N, Je YJ, Yang M, Jiang XH, Ma JH. Pharmacokinetics of baicalin-phospholipid complex in rat plasma and brain tissues after intranasal and intravenous administration. Pharmazie 2011; 66: 374-7.
158. Leveugle B, Ding W, Laurence F, et al. Heparin oligosaccharides that pass the blood-brain barrier inhibit beta-amyloid precursor protein secretion and heparin binding to beta-amyloid peptide. J Neurochem 1998; 70: 736-44.
159. Yoshino S, Watanabe S, Imano M, et al. Improvement of QOL and prognosis by treatment of superfine dispersed lentinan in patients with advanced gastric cancer. Hepatogastroenterology 2010; 57: 172-7.
160. Hazama S, Watanabe S, Ohashi M, et al. Efficacy of orally administered superfine dispersed lentinan (beta-1,3-glucan) for the treatment of advanced colorectal cancer. Anticancer Res 2009; 29: 2611-7.
161. Paetkau ME, Boyd TA, Grace M, Bach-Mills J, Winship B. Senile disciform macular degeneration and smoking. Can J Ophthalmol 1978; 13: 67-71.
162. Xu Q, Park Y, Huang X, et al. Diabetes and risk of Parkinson's disease. Diabetes Care 2011; 34: 910-5.
163. Simon KC, Chen H, Schwarzschild M, Ascherio A. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 2007; 69: 1688-95.
164. Chakravarthy U, Wong TY, Fletcher A, et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol 2010; 10: 31.
165. Ravaglia G, Forti P, Maioli F, et al. Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr 2005; 82: 636-43.